文献速递前列腺癌

磁共振与超声体积测量不一致对前列腺融合活检结果的影响

Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes.
PubMed 文献 · J Urol · 2024-12-10

这项回顾性单中心研究纳入2010年至2023年间连续接受磁共振/超声靶向融合活检和系统活检的4177例患者,评估磁共振与超声体积测量差异与融合活检结果的关系。磁共振体积显著小于超声体积(中位数54 mL vs 56 mL,P < .001),体积不一致超过5 mL后融合活检的附加诊断获益逐渐降低。

要点

  • 磁共振体积显著小于超声体积(中位数54 mL vs 56 mL,P < .001)。
  • 体积不一致≤5 mL时,融合活检检出更多侵袭性肿瘤的患者数为系统活检的4倍(136例 vs 32例,P < .001)。
  • 体积不一致超过5 mL后,融合活检相比系统活检的附加诊断获益逐渐降低。

核心结论

  • 磁共振/超声靶向融合活检检出的前列腺癌虽多于系统活检,但磁共振与超声体积测量不一致越大,融合活检的表现越下降。
  • 作者认为,认识到磁共振与超声体积测量的不一致应提醒操作者融合活检表现可能降低。

研究设计与样本

  • 回顾性单中心研究,纳入2010年至2023年间连续接受磁共振/超声靶向融合活检和系统活检的4177例患者。
  • 活检指征为PSA升高或多参数磁共振结果异常。
  • 超声体积采用三平面椭球公式计算,磁共振体积采用半自动平面分割法获得。

主要发现

  • 2736例(66%)患者活检检出前列腺癌。
  • 在两种技术均检出前列腺癌的病例中(1695/2736,62%),磁共振/超声靶向融合活检较系统活检有更高比例患者具有更高Gleason评分(343例[20.2%] vs 137例[8.1%],P < .001)。
  • 磁共振体积测量显著小于超声体积测量(中位数[IQR] 54 mL [39-77] vs 56 mL [40-80],P < .001)。
  • 体积不一致超过5 mL后,磁共振/超声靶向融合活检相比系统活检的附加诊断获益逐渐降低。
  • 在体积不一致≤5 mL的队列中,磁共振/超声靶向融合活检检出更多侵袭性肿瘤的患者数为系统活检的4倍(136例 vs 32例,P < .001)。

临床怎么用

  • 作者认为,认识到磁共振与超声体积测量的不一致应提醒操作者磁共振/超声靶向融合活检表现可能降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to determine whether the difference between MRI-based and ultrasound (US)-based volume measurements are associated with MRI/US-targeted fusion-guided biopsy outcomes. MATERIALS AND METHODS: This retrospective, single-center study involved 4177 consecutive patients biopsied between 2010 and 2023 using both MRI/US-targeted fusion and systematic biopsy. Biopsies were indicated because of elevated PSA levels or abnormal multiparametric MRI results. US volume measurements were calculated using the triplane ellipsoid formula, and MRI volumes were obtained by semiautomatic planimetric segmentation. Performance of fusion biopsy compared with systematic biopsy was analyzed with respect to the discordance between MRI and US volume measurements. RESULTS: In 2736 patients (66%), biopsy detected prostate cancer. In cases where both techniques yielded prostate cancers (1695/2736 [62%]), a statistically higher proportion of patients had higher Gleason scores on MRI/US-targeted fusion biopsy compared with systematic biopsy (343 patients [20.2%] vs 137 patients [8.1%], P < .001). MRI volume measurements were significantly smaller compared with US volume measurements (median [IQR] 54 mL [39-77], 56 mL [40-80], respectively, P < .001). Beyond 5 mL volume discordance, MRI/US-targeted fusion biopsy gradually showed less added diagnostic benefit compared with systematic biopsy. In the ≤ 5 mL cohort, MRI/US-targeted fusion biopsy detected more aggressive tumors in 4 times as many patients as systematic biopsy (136 vs 32 patients, P < .001). CONCLUSIONS: Although MRI/US-targeted fusion biopsy detected more prostate cancers than systematic biopsy, the performance of MRI/US-targeted fusion biopsy declined with more discordance between volumes measured in MRI vs US. Awareness of volume discordance in MRI- and US-based volume measurements should alert the operator about the possibility of reduced performance of MRI/US-targeted fusion biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Borde T, Varble NA, Hazen LA, et al. Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes. J Urol. 2024. PMID: 39657598. doi:10.1097/JU.0000000000004368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。